Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
AssigneeCorixa Corporation
InventorsJory R. Baldridge, David A. Johnson, Christopher W. Cluff
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ cyclic AGPs for selectively stimulating immune responses in animals and plants.
Claims63
A method for ameliorating or substantially preventing an infectious disease, autoimmune disease or allergic condition in a subject comprising contacting the subject with an effective amount of one or more compounds having the formula:
- 10
- and pharmaceutically acceptable salts there of, wherein X is a member selected from the group consisting of —O— and —NH—;
- Y is a member selected from the group consisting of —O— and —S—;
- R1, R2 and R3 are each members independently selected from the group consisting of (C2-C20)acyl;
- R4 is a member selected from the group consisting of —H and —PO3R7R8,wherein R7 and R8 are each members independently selected from the group consisting of —H and (C1-C4)aliphatic groups;
- R5 is a member selected from the group consisting of —H, —CH3 and —PO3R9R10, wherein R9 and R10 are each members independently selected from the group consisting of —H and (C1-C4)aliphatic groups;
- R6 is selected from H, OH, (C1-C4)oxyaliphatic groups, —PO3R11R12, —OPO3R11R12, —SO3R11, —OSO3R11, —NR11R12, —SR11, —CN, —NO2, —CHO, —CO2R11, and —CONR11R12, wherein R11 and R12 are each independently selected from H and (C1-C4)aliphatic groups, with the provisos that one of R4 and R5 is a phosphorus-containing group and that when R4 is —PO3R7R8, R5 is other than —PO3R9R10;
- wherein “*1”, “*2”, “*3” and “**” represent chiral centers;
- wherein n, m, p and q are each independently an integer from 0 to 6, with the proviso that the sum of p and m is from 0 to 6.
A method for prophylactic treatment of a bacterial or viral infection in a subject comprising contacting the subject with an effective amount of one or more compounds having the formula:
- 11
- and a pharmaceutically acceptable salts there of, wherein X is a member selected from the group consisting of —O— and —NH—;
- Y is a member selected from the group consisting of —O— and —S—;
- R1, R2 and R3 are each members independently selected from the group consisting of (C2-C20)acyl;
- R4 is a member selected from the group consisting of —H and —PO3R7R8, wherein R7 and R8 are each members independently selected from the group consisting of —H and (C1-C4)aliphatic groups;
- R5 is a member selected from the group consisting of —H, —CH3 and —PO3R9R10, wherein R9 and R10 are each members independently selected from the group consisting of —H and (C1-C4)aliphatic groups;
- R6 is selected from H, OH, (C1-C4)oxyaliphatic groups, —PO3R11R12, OPO3R11R12, —SO3R11, —OSO3R11, —NR11R12, —SR11, —CN, —NO2, —CHO, —CO2R11, and —CONR11R12, wherein R11 and R12 are each independently selected from H and (C1-C4)aliphatic groups, with the provisos that one of R4 and R5 is a phosphorus-containing group and that when R4 is —PO3R7R8, R5 is other than —PO3R9R10;
- wherein “*1”, “*2”, “*3”, and “**” represent chiral centers;
- wherein n, m, p and q are each independently an integer from 0 to 6, with the proviso that the sum of p and m is from 0 to 6.
A composition formulated and administered in the absence of exogenous antigen comprising one or more compounds having the formula:
- 12
- and pharmaceutically acceptable salts thereof, wherein X is a member selected from the group consisting of —O— and —NH—;
- Y is a member selected from the group consisting of —O— and —S—;
- R1, R2 and R3 are each members independently selected from the group consisting of (C2-C20)acyl;
- R4 is a member selected from the group consisting of —H and —PO3R7R8, wherein R7 and R8 are each members independently selected from the group consisting of —H and (C1-C4)aliphatic groups;
- R5 is a member selected from the group consisting of —H, —CH3 and —PO3R9R10, wherein R9 and R10 are each members independently selected from the group consisting of —H and (C1-C4)aliphatic groups;
- R6 is selected from H, OH, (C1-C4)oxyaliphatic groups, —PO3R11R12, —OPO3R11R12, —SO3R11, —OSO3R11, —NR11R12, —SR11, —CN, —NO2, —CHO, —CO2R11, and —CONR11R12, wherein R11 and R12 are each independently selected from H and (C1-C4)aliphatic groups, with the provisos that one of R4 and R5 is a phosphorus-containing group and that when R4 is —PO3R7R8, R5 is other than —PO3R9R10;
- wherein “*1”, “*2”, “*3” and “**” represent chiral centers;
- wherein n, m, p and q are each independently an integer from 0 to 6, with the proviso that the sum of p and m is from 0 to 6;
- in combination with a pharmaceutically acceptable carrier.
A method for ameliorating or substantially preventing an infectious disease, autoimmune disease or allergic condition in a subject comprising contacting the subject with an effective amount of a cyclic AGP.
Dependencies are inferred from the claim text.